{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T10:15:25Z","timestamp":1776507325284,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"DOI":"10.1007\/s00108-023-01482-5","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T17:46:05Z","timestamp":1675273565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Progressionshemmung bei chronischen Nierenerkrankungen","Retarding progression of chronic kidney disease"],"prefix":"10.1007","author":[{"given":"Turgay","family":"Saritas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"1482_CR1","first-page":"S1","volume":"39","author":"Anonymous","year":"2002","unstructured":"Anonymous (2002) K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1\u2013S266","journal-title":"Am J Kidney Dis"},{"key":"1482_CR2","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL, Agarwal\u00a0R, Anker\u00a0SD et\u00a0al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N\u00a0Engl J Med 383:2219\u20132229","journal-title":"N Engl J Med"},{"key":"1482_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210639","author":"S Bhandari","year":"2022","unstructured":"Bhandari\u00a0S, Mehta\u00a0S, Khwaja\u00a0A et al (2022) Renin-Angiotensin system inhibition in advanced chronic kidney disease. N\u00a0Engl J Med 387:2021\u20132032. https:\/\/doi.org\/10.1056\/NEJMoa2210639","journal-title":"N Engl J Med"},{"key":"1482_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/ndt\/gfx085","volume":"33","author":"P Chauveau","year":"2017","unstructured":"Chauveau\u00a0P, Aparicio\u00a0M, Bellizzi\u00a0V et\u00a0al (2017) Mediterranean diet as the diet of choice for patients with chronic kidney disease. Nephrol Dial Transplant 33:725\u2013735","journal-title":"Nephrol Dial Transplant"},{"key":"1482_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007004.pub4","author":"EY Chung","year":"2020","unstructured":"Chung\u00a0EY, Ruospo\u00a0M, Natale\u00a0P et\u00a0al (2020) Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD007004.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"1482_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11892-015-0625-2","volume":"15","author":"NG Docherty","year":"2015","unstructured":"Docherty\u00a0NG, Canney\u00a0AL, Le Roux\u00a0CW (2015) Weight loss interventions and progression of diabetic kidney disease. Curr Diab Rep 15:55","journal-title":"Curr Diab Rep"},{"key":"1482_CR7","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1055\/a-1908-5163","volume":"147","author":"K-U Eckardt","year":"2022","unstructured":"Eckardt\u00a0K\u2011U, Binet\u00a0I, De Groot\u00a0K et al (2022) Nomenklatur f\u00fcr Nierenfunktion und Nierenkrankheiten \u2013 Durch Pr\u00e4zision und Verst\u00e4ndlichkeit zu besserer Erfassung und Prognose. Dtsch Med Wochenschr 147:1398\u20131406","journal-title":"Dtsch Med Wochenschr"},{"key":"1482_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.kint.2020.10.022","volume":"99","author":"J Floege","year":"2021","unstructured":"Floege\u00a0J, Johnson\u00a0RJ (2021) Hyperuricemia and progression of chronic kidney disease: to treat or not to treat? Kidney Int 99:14\u201316","journal-title":"Kidney Int"},{"key":"1482_CR9","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman\u00a0KJ, Marquez\u00a0N, Dolgert\u00a0A et al (2018) Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195\u00a0countries and territories. Lancet 392:2052\u20132090","journal-title":"Lancet"},{"key":"1482_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac254","author":"RT Gansevoort","year":"2023","unstructured":"Gansevoort\u00a0RT, Anders\u00a0HJ, Cozzolino\u00a0M et al (2023) What should European nephrology do with the new CKD-EPI equation? Nephrol Dial Transplant 38(1):1\u20136. https:\/\/doi.org\/10.1093\/ndt\/gfac254","journal-title":"Nephrol Dial Transplant"},{"key":"1482_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/ki.2011.157","volume":"80","author":"SI Hallan","year":"2011","unstructured":"Hallan\u00a0SI, Orth\u00a0SR (2011) Smoking is a\u00a0risk factor in the progression to kidney failure. Kidney Int 80:516\u2013523","journal-title":"Kidney Int"},{"key":"1482_CR12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, Stef\u00e1nsson\u00a0BV, Correa-Rotter\u00a0R et al (2020) Dapagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med 383:1436\u20131446","journal-title":"N Engl J Med"},{"key":"1482_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","author":"WG Herrington","year":"2023","unstructured":"Herrington\u00a0WG, Staplin\u00a0N, Wanner\u00a0C et\u00a0al (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med. 388(2):117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"1482_CR14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/kisup.2012.37","volume":"2","author":"KDIGO","year":"2012","unstructured":"KDIGO (2012) Clinical practice guideline for Anaemia in chronic kidney disease. Kidney Int Suppl 2:279\u2013335. https:\/\/doi.org\/10.1038\/kisup.2012.37","journal-title":"Kidney Int Suppl"},{"issue":"Suppl","key":"1482_CR15","first-page":"5","volume":"3","author":"Kidney Disease Improving Global Outcomes (KDIGO)","year":"2013","unstructured":"Kidney Disease Improving Global Outcomes (KDIGO) (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 3(Suppl):5\u201314","journal-title":"Kidney Int"},{"key":"1482_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group (2021) KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99:S1\u2013S87","journal-title":"Kidney Int"},{"key":"1482_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ki.2012.74","volume":"82","author":"HJ Lambers Heerspink","year":"2012","unstructured":"Lambers Heerspink\u00a0HJ, Holtkamp\u00a0FA, Parving\u00a0HH et\u00a0al (2012) Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 82:330\u2013337","journal-title":"Kidney Int"},{"key":"1482_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2215\/CJN.07990520","volume":"16","author":"NE Madias","year":"2021","unstructured":"Madias\u00a0NE (2021) Metabolic acidosis and CKD progression. Clin J Am Soc Nephrol 16:310\u2013312","journal-title":"Clin J Am Soc Nephrol"},{"key":"1482_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00092-017-1625-0","volume":"21","author":"TN Meyer","year":"2017","unstructured":"Meyer\u00a0TN (2017) Proteinurie. Uro-News 21:38\u201341. https:\/\/doi.org\/10.1007\/s00092-017-1625-0","journal-title":"Uro-News"},{"key":"1482_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.7326\/M20-5938","volume":"174","author":"SD Navaneethan","year":"2021","unstructured":"Navaneethan\u00a0SD, Zoungas\u00a0S, Caramori\u00a0ML et\u00a0al (2021) Diabetes management in chronic kidney disease: synopsis of the 2020 KDIGO clinical practice guideline. Ann Intern Med 174:385\u2013394","journal-title":"Ann Intern Med"},{"key":"1482_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1681\/ASN.2013040392","volume":"25","author":"C Robinson-Cohen","year":"2014","unstructured":"Robinson-Cohen\u00a0C, Littman\u00a0AJ, Duncan\u00a0GE et al (2014) Physical activity and change in estimated GFR among persons with CKD. J\u00a0Am Soc Nephrol 25:399\u2013406","journal-title":"J Am Soc Nephrol"},{"key":"1482_CR22","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/j.ekir.2022.01.231","volume":"7","author":"M Schneider","year":"2022","unstructured":"Schneider\u00a0M, Peach\u00a0E, Salvatore\u00a0B et al (2022) POS-213 REVEAL-CKD: prevalence of undiagnosed early chronic kidney disease in Germany. Kidney Int Rep 7:S93","journal-title":"Kidney Int Rep"},{"key":"1482_CR23","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens\u00a0PE, Levin\u00a0A (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825\u2013830","journal-title":"Ann Intern Med"},{"key":"1482_CR24","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","volume":"380","author":"M Tonelli","year":"2012","unstructured":"Tonelli\u00a0M, Muntner\u00a0P, Lloyd\u00a0A et al (2012) Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a\u00a0population-level cohort study. Lancet 380:807\u2013814","journal-title":"Lancet"},{"key":"1482_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M13-2453","volume":"160","author":"M Tonelli","year":"2014","unstructured":"Tonelli\u00a0M, Wanner\u00a0C (2014) Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med 160:182","journal-title":"Ann Intern Med"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01482-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01482-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01482-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T17:46:46Z","timestamp":1675273606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01482-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":25,"alternative-id":["1482"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01482-5","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]},"assertion":[{"value":"23 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0Saritas und J.\u00a0Floege geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}